# US 2025/0144245 A1 · Gene therapy for arrhythmogenic cardiomyopathy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144245 A1
- Document ID: US20250144245A1
- Status: Published application
- Kind: A1
- Application number: 18/838,928
- Filed: 2023-02-17
- Published: 2025-05-08
- Earliest claimed: 2022-02-18
- Assignees: Ginkgo Bioworks, Inc.
- Applicants: Ginkgo Bioworks, Inc.
- Inventors: John Graef; Chicheng Sun
- Web page: https://patentgrep.com/patent/US20250144245A1

## CPC

- A61K 48/0058: {Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}
- A61K 35/761: Adenovirus
- A61K 38/1709: {from mammals}
- A61K 48/0041: {the non-active part being polymeric}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61K 48/0066: {Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid}
- C07K 14/4716: {Muscle proteins, e.g. myosin, actin}
- C12N 15/86: Viral vectors
- A61K 48/0075: {characterised by an aspect of the delivery route, e.g. oral, subcutaneous}
- C12N 15/907: {in mammalian cells}
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2830/42: being an intron or intervening sequence for splicing and/or stability of RNA
- C12N 2830/50: regulating RNA stability, not being an intron, e.g. poly A signal
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The disclosure provides nucleic acids (comprising AAV expression cassettes), AAV vectors, and compositions for use in methods for treating and/or delaying the onset of diseases associated with mutations in genes, such as PKP2, associated with arrhythmogenic cardiomyopathy. Also, provided herein are methods for treating and/or delaying the onset of arrhythmogenic cardiomyopathy.

## Claims

### Claim 1

A nucleic acid molecule, comprising an adeno-associated virus (AAV) expression cassette, wherein the AAV expression cassette comprises, from 5′ to 3′:
(i) a 5′ AAV inverted terminal repeat (ITR);
(ii) a promoter;
(iii) an arrhythmogenic cardiomyopathy-associated transgene; and
(iv) a 3′ AAV ITR.

### Claim 2 (depends on 1)

The nucleic acid molecule of claim 1, wherein the promoter drives expression of the arrhythmogenic cardiomyopathy-associated transgene.

### Claim 3 (depends on 1, 2)

The nucleic acid molecule of claim 1 or 2, wherein the promoter is capable of expressing the transgene in a cardiac cell.

### Claim 4 (depends on 1, 2, 3)

The nucleic acid molecule of any one of claims 1-3, wherein the promoter comprises a cardiac troponin T (TNNT2) promoter.

### Claim 5 (depends on 4)

The nucleic acid molecule of claim 4, wherein the TNNT2 promoter comprises a nucleic acid sequence derived from: (i) a human TNNT2 promoter, (ii) a chicken TNNT2 promoter, (iii) a mouse TNNT2 promoter, or (iv) any combination thereof.

### Claim 6 (depends on 5)

The nucleic acid molecule of claim 5, wherein the TNNT2 promoter comprises a human TNNT2 promoter.

### Claim 7 (depends on 4, 5, 6)

The nucleic acid molecule of any one of claims 4-6, wherein the TNNT2 promoter comprises the nucleic acid sequence SEQ ID NO: 4, or a sequence at least 90% identical thereto.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The nucleic acid molecule of any one of claims 1-7, wherein the transgene encodes a plakophilin-2.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The nucleic acid molecule of any one of claims 1-8, wherein the transgene encodes a human plakophilin-2.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The nucleic acid molecule of any one of claims 1-9, wherein the transgene encodes an isoform 2a of human plakophilin-2.

### Claim 11 (depends on 10)

The nucleic acid molecule of claim 10, wherein the isoform 2a of human plakophilin-2 comprises the amino acid sequence of SEQ ID NO: 1, or a sequence at least 90% identical thereto.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The nucleic acid molecule of any one of claims 1-11, wherein the transgene encodes an RNA transcript variant 2a of the PKP2 gene.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The nucleic acid molecule of any one of claims 1-12, wherein the transgene comprises a PKP2 gene.

### Claim 14 (depends on 13)

The nucleic acid molecule of claim 13, wherein the PKP2 gene is a human PKP2 gene.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The nucleic acid molecule of any one of claims 1-14, wherein the transgene comprises the nucleic acid sequence of SEQ ID NO: 2, or a sequence at least 90% identical thereto.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The nucleic acid molecule of any one of claims 1-15, wherein at least one of the 5′ ITR and the 3′ ITR is about 110 to about 160 nucleotides in length.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The nucleic acid molecule of any one of claims 1-16, wherein the 5′ ITR is the same length as the 3′ ITR.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The nucleic acid molecule of any one of claims 1-17, wherein the 5′ ITR and the 3′ ITR have different lengths.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The nucleic acid molecule of any one of claims 1-18, wherein the 5′ ITR and the 3′ ITR are each about 141 nucleotides in length.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The nucleic acid molecule of any one of claims 1-19, wherein at least one of the 5′ ITR and the 3′ ITR is isolated or derived from the genome of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAVrh8, AAVrh10, AAVrh32.33, AAVrh74, Avian AAV or Bovine AAV.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The nucleic acid molecule of any one of claims 1-20, wherein the 5′ ITR and the 3′ ITR are each isolated or derived from the genome of AAV2.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The nucleic acid molecule of any one of claims 1-21, wherein the 5′ ITR comprises the sequence of SEQ ID NO: 5.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The nucleic acid molecule of any one of claims 1-22, wherein the 3′ ITR comprises the sequence of SEQ ID NO: 6.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The nucleic acid molecule of any one of claims 1-23, wherein the AAV expression cassette comprises an intron.

### Claim 25 (depends on 24)

The nucleic acid molecule of claim 24, wherein the intron is derived from the human beta-globin gene.

### Claim 26 (depends on 24, 25)

The nucleic acid molecule of claim 24 or claim 25, wherein the intron comprises a nucleic acid sequence of SEQ ID NO: 7, or a sequence at least 90% identical thereto.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The nucleic acid molecule of any one of claims 1-26, wherein the AAV expression cassette comprises a polyadenylation signal.

### Claim 28 (depends on 27)

The nucleic acid molecule of claim 27, wherein the polyadenylation signal is a polyadenylation signal isolated or derived from one or more of the following genes: simian virus 40 (SV40), rBG, α-globin, β-globin, human collagen, human growth hormone (hGH), polyoma virus, human growth hormone (hGH) or bovine growth hormone (bGH).

### Claim 29 (depends on 27, 28)

The nucleic acid molecule of claim 27 or claim 28, wherein the AAV expression cassette comprises a bGH polyadenylation signal.

### Claim 30 (depends on 29)

The nucleic acid molecule of claim 29, wherein the bGH polyadenylation signal comprises a nucleic acid sequence of SEQ ID NO: 8, or a sequence at least 90% identical thereto.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The nucleic acid molecule of any one of claims 1-30, wherein the AAV expression cassette comprises at least one stuffer sequence.

### Claim 32 (depends on 31)

The nucleic acid molecule of claim 31, wherein the at least one stuffer sequence comprises a nucleic acid sequence of SEQ ID NO: 9, or a sequence at least 90% identical thereto.

### Claim 33 (depends on 31)

The nucleic acid molecule of claim 31, wherein the at least one stuffer sequence comprises a nucleic acid sequence of SEQ ID NO: 9, or a portion thereof.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The nucleic acid molecule of any one of claims 1-33, wherein the AAV expression cassette comprises a Kozak sequence.

### Claim 35 (depends on 34)

The nucleic acid molecule of claim 34, wherein the Kozak sequence comprises a nucleic acid sequence of SEQ ID NO: 10, or a sequence at least 90% identical thereto; or a nucleic acid sequence of acagccacc, or a sequence at least 90% identical thereto.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The nucleic acid molecule of any one of claims 1-35, wherein the AAV expression cassette comprises an enhancer.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The nucleic acid molecule of any one of claims 1-36, wherein the AAV expression cassette comprises a nucleic acid sequence SEQ ID NO: 12, or a sequence at least 90% identical thereto.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

A plasmid, comprising the nucleic acid molecule of any one of claims 1-37.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

A cell, comprising the nucleic acid molecule of any one of claims 1-37 or the plasmid of claim 38.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

A method of producing a recombinant AAV vector, the method comprising contacting an AAV producer cell with the nucleic acid molecule of any one of claims 1-37 or the plasmid of claim 38.

### Claim 41 (depends on 40)

A recombinant AAV vector produced by the method of claim 40.

### Claim 42 (depends on 41)

The recombinant AAV vector of claim 41, wherein the vector is of a serotype selected from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAVrh8, AAVrh10, AAVrh32.33, AAVrh74, Avian AAV and Bovine AAV.

### Claim 43 (depends on 41, 42)

The recombinant AAV vector of claim 41 or claim 42, wherein the recombinant AAV vector is a single-stranded AAV (ssAAV).

### Claim 44 (depends on 41, 42)

The recombinant AAV vector of claim 41 or claim 42, wherein the recombinant AAV vector is a self-complementary AAV (scAAV).

### Claim 45 (depends on 41, 42, 43, 44)

The recombinant AAV vector of any one of claims 41-44, wherein the AAV vector comprises a capsid protein of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAVrh8, AAVrh10, AAVrh32.33, AAVrh74, Avian AAV or Bovine AAV.

### Claim 46 (depends on 41, 42, 43, 44, 45)

The recombinant AAV vector of any one of claims 41-45, wherein the AAV vector comprises a capsid protein with one or more substitutions or mutations, as compared to a wild type AAV capsid protein.

### Claim 47 (depends on 41, 42, 43, 44, 45, 46)

The recombinant AAV vector of any one of claims 41-46, wherein the AAV vector comprises a capsid protein comprising:
a. (i) the amino acid sequence of SEQ ID NO: 13, or a sequence at least 90% identical thereto, or
b. (ii) the amino acid sequence of SEQ ID NO: 14, or a sequence at least 90% identical thereto, or
c. (iii) the amino acid sequence of SEQ ID NO: 15, or a sequence at least 90% identical thereto.

### Claim 48 (depends on 47)

The recombinant AAV vector of claim 47, wherein the AAV vector comprises a capsid protein comprising the amino acid sequence of SEQ ID NO: 13, or a sequence at least 90% identical thereto.

### Claim 49 (depends on 48)

The recombinant AAV vector of claim 48, wherein the AAV vector comprises a capsid protein comprising the amino acid sequence of SEQ ID NO: 13.

### Claim 50 (depends on 47)

The recombinant AAV vector of claim 47, wherein the AAV vector comprises a capsid protein comprising the amino acid sequence of SEQ ID NO: 14, or a sequence at least 90% identical thereto.

### Claim 51 (depends on 50)

The recombinant AAV vector of claim 50, wherein the AAV vector comprises a capsid protein comprising the amino acid sequence of SEQ ID NO: 14.

### Claim 52 (depends on 47)

The recombinant AAV vector of claim 47, wherein the AAV vector comprises a capsid protein comprising the amino acid sequence of SEQ ID NO: 15, or a sequence at least 90% identical thereto.

### Claim 53 (depends on 52)

The recombinant AAV vector of claim 52, wherein the AAV vector comprises a capsid protein comprising the amino acid sequence of SEQ ID NO: 15.

### Claim 54 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53)

A composition, comprising: (a) the nucleic acid molecule of any one of claims 1-37, the plasmid of claim 38, the cell of claim 39, or the recombinant AAV vector of any one of claims 41-53; and (b) a pharmaceutically acceptable carrier.

### Claim 55 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

A method of expressing an arrhythmogenic cardiomyopathy-associated transgene in a tissue, comprising: contacting the tissue with the nucleic acid molecule of any one of claims 1-37, the plasmid of claim 38, the recombinant AAV vector of any one of claims 41-53, or the composition of claim 54, thereby expressing the arrhythmogenic cardiomyopathy-associated transgene in the tissue.

### Claim 56 (depends on 55)

The method of claim 55, wherein the tissue comprises one or more cells, and one or more desmosomal junctions.

### Claim 57 (depends on 55, 56)

The method of claim 55 or claim 56, wherein the one or more cells are cardiac cells, endothelial cells, skin cells, bladder cells, or gastrointestinal mucosal cells.

### Claim 58 (depends on 57)

The method of claim 57, wherein the one or more cells are cardiac cells.

### Claim 59 (depends on 55, 56, 57, 58)

The method of any one of claims 55-58, wherein the contacting step is performed in vitro, ex vivo, or in vivo.

### Claim 60 (depends on 59)

The method of claim 59, wherein the contacting step is performed in vivo in a subject in need thereof.

### Claim 61 (depends on 60)

The method of claim 60, wherein the contacting step comprises administering a therapeutically effective amount of the nucleic acid molecule, the plasmid, the recombinant AAV vector, or the composition to the subject.

### Claim 62 (depends on 60, 61)

The method of claim 60 or claim 61, wherein the subject suffers from, or is at a risk of developing, the arrhythmogenic cardiomyopathy.

### Claim 63 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

A method for treating arrhythmogenic cardiomyopathy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the nucleic acid molecule of any one of claims 1-37, the plasmid of claim 38, the cell of claim 39, the recombinant AAV vector of any one of claims 41-53, or the composition of claim 54, thereby treating arrhythmogenic cardiomyopathy in the subject.

### Claim 64 (depends on 63)

The method of claim 63, wherein the subject suffers from, or is at a risk of developing, the arrhythmogenic cardiomyopathy.

### Claim 65 (depends on 62, 63, 64)

The method of any one of claims 62-64, wherein the arrhythmogenic cardiomyopathy is arrhythmogenic right ventricular cardiomyopathy.

### Claim 66 (depends on 62, 63, 64, 65)

The method of any one of claims 62-65, wherein the arrhythmogenic cardiomyopathy is associated with, promoted by, or caused by a genetic mutation.

### Claim 67 (depends on 66)

The method of claim 66, wherein the genetic mutation comprises a mutation in the PKP2 gene.

### Claim 68 (depends on 67)

The method of claim 67, wherein the mutation in the PKP2 gene results in PKP2 haploinsufficiency.

### Claim 69 (depends on 62, 63, 64, 65, 66, 67, 68)

The method of any one of claims 62-68, wherein the method comprises diminishing the severity of; delaying the onset or progression of; and/or eliminating a symptom of the arrhythmogenic cardiomyopathy.

### Claim 70 (depends on 69)

The method of claim 69, wherein the symptom of the arrhythmogenic cardiomyopathy comprises: (a) re-entrant ventricular tachycardia, (b) syncope, (c) sudden death, or (d) any combination thereof.

### Claim 71 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70)

The method of any one of claims 62-70, wherein the arrhythmogenic cardiomyopathy is associated with: (a) decreased mechanical stability between cardiomyocytes of the subject, (b) disruption of gap junctions in the cardiac tissue of the subject, (c) decreased sodium currents in the cardiac tissue of the subject, (d) fibrosis of the right ventricular myocardium, or (e) any combination thereof.

### Claim 72 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71)

The method of any one of claims 62-71, wherein the method comprises increasing the mechanical stability between cardiomyocytes of the subject, as compared to a control subject having arrhythmogenic cardiomyopathy, wherein the control subject has not been administered the therapeutically effective amount, or as compared to the subject prior to administration of the therapeutically effective amount.

### Claim 73 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72)

The method of any one of claims 62-72, wherein the method comprises improving the function of gap junctions in the cardiac tissue of the subject, as compared to a control subject having arrhythmogenic cardiomyopathy, wherein the control subject has not been administered the therapeutically effective amount, or as compared to the subject prior to administration of the therapeutically effective amount.

### Claim 74 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73)

The method of any one of claims 62-73, wherein the method comprises increasing sodium currents in the cardiac tissue of the subject, as compared to a control subject having arrhythmogenic cardiomyopathy, wherein the control subject has not been administered the therapeutically effective amount, or as compared to the subject prior to administration of the therapeutically effective amount.

### Claim 75 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)

The method of any one of claims 62-74, wherein the method comprises decreasing fibrosis of the right ventricular myocardium of the subject, as compared to a control subject having arrhythmogenic cardiomyopathy, wherein the control subject has not been administered the therapeutically effective amount, or as compared to the subject prior to administration of the therapeutically effective amount.

### Claim 76 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75)

The method of any one of claims 62-75, wherein the method comprises increasing the left ventricular ejection fraction of the heart, as compared to a control subject having arrhythmogenic cardiomyopathy, wherein the control subject has not been administered the therapeutically effective amount, or as compared to the subject prior to administration of the therapeutically effective amount.

### Claim 77 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76)

The method of any one of claims 62-76, wherein the method comprises decreasing the right ventricular area of the heart, as compared to a control subject having arrhythmogenic cardiomyopathy, wherein the control subject has not been administered the therapeutically effective amount, or as compared to the subject prior to administration of the therapeutically effective amount.

### Claim 78 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77)

The method of any one of claims 62-77, wherein the method comprises prolonging the survival of the subject, as compared to a control subject having arrhythmogenic cardiomyopathy, wherein the control subject has not been administered the therapeutically effective amount, or as compared to the expected survival of the subject prior to administration of the therapeutically effective amount.

### Claim 79 (depends on 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78)

The method of any one of claim 60-78, wherein the subject is a human subject.

### Claim 80 (depends on 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79)

The method of any one of claims 60-79, wherein the nucleic acid molecule, the plasmid, the cell, the recombinant AAV vector, or composition is administered to the cardiac tissue of the subject.

### Claim 81 (depends on 80)

The method of claim 80, wherein the nucleic acid molecule, the plasmid, the cell, the recombinant AAV vector, or composition is administered to the left atrium, right atrium, left ventricle, right ventricle and/or septum.

### Claim 82 (depends on 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81)

The method of any one of claims 60-81, wherein the nucleic acid molecule, the plasmid, the cell, the recombinant AAV vector, or composition is administered to the subject via intravenous administration, intra-arterial administration, intra-aortic administration, direct cardiac injection, coronary artery perfusion, or any combination thereof.
